Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-002 in acute coronary syndromes
2009-016812-18Phase 3Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of varespladib methyl in acute coronary syndrome (ACS) (2 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Time to first major adverse cardiovascular event. Started Jun 2010; status: terminated.
02
Drugs
varespladib methyl
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2009-016812-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016812-18.